Genetics of neurological disorders

Neurological diseases are defined as an inappropriate function of the peripheral or central nervous system due to impaired electrical impulses throughout the brain and/or nervous system that may present with heterogeneous symptoms according to the parts of the system involved in these pathologic processes. Growing evidence on genetic components of neurological disease have been collected during recent years. Genetic studies have opened the way for understanding the underlying pathology of many neurological disorders. The outcome of current intense research into the genetics of neurological disorders will hopefully be the introduction of new diagnostic tools and the discovery of potential targets for new and more effective medications and preventive measures.

[1]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[2]  J Kirchheiner,et al.  Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. , 2003, Pharmacopsychiatry.

[3]  W. Kamphorst,et al.  Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R , 2003, Annals of neurology.

[4]  L. Feuk,et al.  Genetic variation in a haplotype block spanning IDE influences Alzheimer disease , 2003, Human mutation.

[5]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[6]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[7]  A Ghetti,et al.  Lifestyle‐related risk factors for Parkinson's disease: a population‐based study , 2003, Acta neurologica Scandinavica.

[8]  R. Kerwin,et al.  Advances in the pharmacogenetic prediction of antipsychotic response. , 2003, Toxicology.

[9]  Cecil M. Burchfiel,et al.  Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study , 2003, Journal of Neurology.

[10]  R. Cacabelos.  The application of functional genomics to Alzheimer's disease. , 2003, Pharmacogenomics.

[11]  R. Martins,et al.  Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer’s disease , 2003, Neurobiology of Aging.

[12]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[13]  J. Dartigues,et al.  Association between Parkinson’s Disease and Exposure to Pesticides in Southwestern France , 2003, Neuroepidemiology.

[14]  M. Hernán,et al.  Alcohol consumption and the incidence of Parkinson's disease , 2003, Annals of neurology.

[15]  J. Haines,et al.  Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. , 2003, American journal of human genetics.

[16]  W. Weiner,et al.  From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease , 2003, Current opinion in neurology.

[17]  R. Blakely,et al.  Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.

[18]  J. Mate,et al.  Methionine synthase polymorphism is a risk factor for Alzheimer disease , 2003, Neuroreport.

[19]  D. Pickar.  Pharmacogenomics of psychiatric drug treatment. , 2003, The Psychiatric clinics of North America.

[20]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[21]  M. Tohyama,et al.  [Recent progress in 'HMGA1a' which causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[22]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Morgan.  Antibody therapy for Alzheimer’s disease , 2003, Expert review of vaccines.

[24]  G. Roks.  [Alzheimer's disease. Present and future role of genetics]. , 2003, Tijdschrift voor Gerontologie en Geriatrie.

[25]  A Hofman,et al.  Genetic epidemiology of amyotrophic lateral sclerosis , 2003, Clinical genetics.

[26]  J. Trojanowski,et al.  Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. , 2003, Science of aging knowledge environment : SAGE KE.

[27]  Akihiko Takashima,et al.  Chaperones increase association of tau protein with microtubules , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Yi Zhao,et al.  Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability , 2003, Neuroscience Letters.

[29]  M. Hasegawa,et al.  A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology , 2003, Annals of neurology.

[30]  N. Bonini.  Chaperoning brain degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[32]  Nutan Sharma,et al.  TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.

[33]  Hreinn Stefánsson,et al.  A susceptibility gene for late‐onset idiopathic Parkinson's disease , 2002, Annals of neurology.

[34]  D. Small,et al.  Proteolytic processing of the amyloid-beta protein precursor of Alzheimer's disease. , 2002, Essays in biochemistry.

[35]  John Q Trojanowski,et al.  An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype , 2002, Annals of neurology.

[36]  J. Nakura,et al.  The 4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. , 2002, Internal medicine.

[37]  Steven G Potkin,et al.  Pharmacogenomics in schizophrenia: the quest for individualized therapy. , 2002, Human molecular genetics.

[38]  S. DeKosky,et al.  Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12 , 2002, Human Genetics.

[39]  J. Gilbert,et al.  Defective neuronal sprouting by human apolipoprotein E4 is a gain‐of‐negative function , 2002, Journal of neuroscience research.

[40]  N. Schupf,et al.  Genetic and host factors for dementia in Down's syndrome. , 2002, The British journal of psychiatry : the journal of mental science.

[41]  F. Panza,et al.  F175S Change and a Novel Polymorphism in Presenilin-1 Gene in Late-Onset Familial Alzheimer’s Disease , 2002, European Neurology.

[42]  B. Ghetti,et al.  A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum , 2002, Acta Neuropathologica.

[43]  T. Iwatsubo,et al.  Late‐onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation , 2002, Annals of neurology.

[44]  S. Frantz,et al.  Set back to Alzheimer vaccine studies , 2002, Nature Medicine.

[45]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[46]  W. Kamphorst,et al.  A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease , 2002, Annals of neurology.

[47]  R. Cacabelos.  Pharmacogenomics for the treatment of dementia , 2002, Annals of medicine.

[48]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[49]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[50]  P. Seubert,et al.  Immunotherapy with β-Amyloid for Alzheimer's Disease: A New Frontier , 2001 .

[51]  K. Nakashima,et al.  [Analysis of causative genes and genetic risk factor in Alzheimer's disease]. , 2001, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[52]  R. Crowther,et al.  Pick's disease associated with the novel Tau gene mutation K369I , 2001, Annals of neurology.

[53]  E. Mufson,et al.  Apolipoprotein E immunoreactivity in neurons and neurofibrillary degeneration of aged non‐demented and alzheimer's disease patients , 2001, Microscopy research and technique.

[54]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[55]  R. Tanzi,et al.  Of replications and refutations: The status of Alzheimer’s disease genetic research , 2001, Current neurology and neuroscience reports.

[56]  Kyoko Suzuki,et al.  Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells , 2001, Acta Neuropathologica.

[57]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[58]  J. Houwing-Duistermaat,et al.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. , 2001, American journal of human genetics.

[59]  B. Strooper,et al.  Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability , 2001 .

[60]  T. Tabira,et al.  Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11‐splice site in the tau gene , 2001, Annals of neurology.

[61]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[62]  C. Klein.  [The genetics of Parkinson syndrome]. , 2001, Praxis.

[63]  M. Farrer,et al.  Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter , 2001, Neurobiology of Disease.

[64]  P. Chapman,et al.  Genes, models and Alzheimer's disease. , 2001, Trends in genetics : TIG.

[65]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[66]  A. Bentivoglio,et al.  Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.

[67]  W D Heiss,et al.  Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial Parkinsonism associated with mutations in the Parkin gene , 2001, Annals of neurology.

[68]  K. Kohara,et al.  Genetic Association between Alzheimer Disease and the Alpha-Synuclein Gene , 2001, Dementia and Geriatric Cognitive Disorders.

[69]  S. Scherer,et al.  Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. , 2001, Genomics.

[70]  A A Hicks,et al.  Familial aggregation of Parkinson's disease in Iceland. , 2000, The New England journal of medicine.

[71]  J. Grafman,et al.  Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation , 2000, Annals of neurology.

[72]  R. Cacabelos,et al.  A pharmacogenomic approach to Alzheimer’s disease , 2000, Acta neurologica Scandinavica. Supplementum.

[73]  P. Lantos,et al.  A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies , 2000, Annals of neurology.

[74]  C. Haass,et al.  Intramembrane proteolysis by presenilins , 2000, Nature Reviews Molecular Cell Biology.

[75]  J. Haines,et al.  Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. , 2000, JAMA.

[76]  N. Bazan,et al.  Neuroinflammatory Signaling Upregulation in Alzheimer's Disease , 2000, Neurochemical Research.

[77]  M. Gold,et al.  A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease , 2000, Neurology.

[78]  J. Jankovic,et al.  Variability and validity of polymorphism association studies in Parkinson’s disease , 2000, Neurology.

[79]  E P Noble,et al.  The DRD2 gene in psychiatric and neurological disorders and its phenotypes. , 2000, Pharmacogenomics.

[80]  T. Miyakawa,et al.  Late onset X‐linked hydrocephalus with normal cerebrospinal fluid pressure , 2000, Psychiatry and clinical neurosciences.

[81]  M. Polymeropoulos,et al.  Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients , 2000, Neuroreport.

[82]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[83]  B. Ghetti,et al.  Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. , 2000, Archives of neurology.

[84]  P. Schofield,et al.  Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene , 2000 .

[85]  Arya M. Sharma.  Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.

[86]  C. Kumana,et al.  Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.

[87]  F. Jessen,et al.  Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population , 2000, Neuroscience Letters.

[88]  G. Schellenberg,et al.  A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD‐Kumamoto) , 2000, Annals of neurology.

[89]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[90]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[91]  C. Duijn,et al.  Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression. , 2000, Human molecular genetics.

[92]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Guazzelli,et al.  Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. , 1999, Journal of neuropathology and experimental neurology.

[94]  S. Reske,et al.  FTDP‐17: An early‐onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation , 1999, Annals of neurology.

[95]  J. Langston,et al.  Candidate genes and Parkinson's disease: where to next? , 1999, Neurology.

[96]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[97]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[98]  J. Hardy,et al.  Pathways to primary neurodegenerative disease. , 1999, Neurologia.

[99]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[100]  J. B. Martin,et al.  Molecular basis of the neurodegenerative disorders. , 1999, The New England journal of medicine.

[101]  G. Schellenberg,et al.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[103]  M. Graeber,et al.  Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson disease , 1999, Neurogenetics.

[104]  G. Schellenberg,et al.  A distinct familial presenile dementia with a novel missense mutation in the tau gene. , 1999, Neuroreport.

[105]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[106]  M. Pericak-Vance,et al.  Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers , 1998, Neurogenetics.

[107]  R. Jakes,et al.  Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.

[108]  W. Kamphorst,et al.  Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. , 1998, The American journal of pathology.

[109]  Y. Agid,et al.  Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism , 1998, The Lancet.

[110]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[111]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[112]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[113]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[114]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[115]  B. Müller-Myhsok,et al.  A susceptibility locus for Parkinson's disease maps to chromosome 2p13 , 1998, Nature Genetics.

[116]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[117]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[118]  Y Agid,et al.  Mitochondrial Free Radical Signal in Ceramide‐Dependent Apoptosis: A Putative Mechanism for Neuronal Death in Parkinson's Disease , 1997, Journal of neurochemistry.

[119]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[120]  S. Sorbi,et al.  Analysis of apolipoprotein E, α1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man , 1997, Neuroscience Letters.

[121]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[122]  N. Wood.  Genes and parkinsonism. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[123]  A A Schäffer,et al.  Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. , 1997, American journal of human genetics.

[124]  M. Polymeropoulos,et al.  Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.

[125]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[126]  M. Pericak-Vance,et al.  Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease , 1996, The Lancet.

[127]  D. Drachman,et al.  Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease : what physicians know, and what they should know , 1995 .

[128]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[129]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[130]  K. Wilhelmsen,et al.  Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. , 1994, American journal of human genetics.

[131]  T. Iwatsubo,et al.  Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease , 1994, The Lancet.

[132]  K. Marder,et al.  Clinical characteristics of a family with chromosome 17‐linked disinhibition‐dementia‐ parkinsonism‐amyotrophy complex , 1994, Neurology.

[133]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[134]  D. Murman,et al.  Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late‐onset Alzheimer's disease , 1994, Annals of neurology.

[135]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[136]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[137]  R. Mayer,et al.  Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[138]  D. Benson,et al.  Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[139]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[140]  S. H. Joo,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[141]  Bertram Müller-Myhsok,et al.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. , 2004, American journal of human genetics.

[142]  Hong Jiang,et al.  Mutations in NR4A2 associated with familial Parkinson disease , 2003, Nature Genetics.

[143]  E. Noble,et al.  D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[144]  T. Tabira,et al.  A novel mutation at position +11 in the intron following exon 10 of the tau gene in FTDP-17. , 2002, Journal of applied genetics.

[145]  Robert H. Brown,et al.  A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. , 2002, American journal of human genetics.

[146]  S. Shimohama,et al.  Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[147]  N. Kato,et al.  A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease , 2001, Molecular Psychiatry.

[148]  J. Ghika.  [Genetics of parkinsonism]. , 2000, Revue medicale de la Suisse romande.

[149]  P. Schofield,et al.  Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. , 2000, Brain : a journal of neurology.

[150]  M. Farrer,et al.  A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. , 1999, Human molecular genetics.

[151]  M. Farrer,et al.  The genetics of disorders with synuclein pathology and parkinsonism. , 1999, Human molecular genetics.

[152]  B. Dastugue,et al.  [Apolipoprotein E and Alzheimer's disease]. , 1998, Annales de biologie clinique.

[153]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[154]  D. Drachman,et al.  Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. , 1995, Archives of neurology.

[155]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.